Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Bullboard Posts
Comment by bilosellhion Sep 28, 2003 1:03pm
226 Views
Post# 6468069

RE: SEC Ready to Crack Down on Naked Shorters?

RE: SEC Ready to Crack Down on Naked Shorters?and now you may understand better the risks of entrusting money with onc management. if Thompson is prepared to resuce the pros (ie. shorters) from losing their shirt and simultaneously stick the small retail investor with added dilution, what is to prevent him from screwing the small onc shareholder again in a partnership deal, where he (& coffey, etc.) get a 14% personal cut from any royalty off the top? aside from the science, one thing is certain - these guys will make a lot of money off the reovirus if it is proven successful - whether oncolytics and shareholders do so isn't nearly as certain. maybe thats why fund managers are more prepared to step in at much higher prices after a partner has removed much of the risk of these guys running (or perhaps ruining) the story?
Bullboard Posts